IL-17 Targeted Drugs Signal Hope for Hidradenitis Suppurativa Patients

Dermatologist Thrasyvoulos Tzellos discussed exciting advancements in the treatment of Hidradenitis Suppurativa at the EADV congress. New drugs targeting IL-17, such as secukinumab, Bimekizumab and upatacitinib, show very promise in managing inflammation and draining fistulas, surpassing previous anti-TNF treatments.